



## Joint Working Executive Summary

Published on [www.bayer.co.uk](http://www.bayer.co.uk)

|   |   |
|---|---|
| <b>Project title</b>                                    | Improving Capacity and Medical Retina Services for Patients at Yeovil Hospital  |
| <b>Project partners</b>                                 | Yeovil District Hospital NHS Foundation Trust<br>Bayer plc  |
| <b>Project summary</b>                                  | <p>The ophthalmology service in Yeovil has grown significantly over the last 4 years and has now reached a point where demand is outstripping capacity therefore investment is required to redesign the service to make improvements which will enable demand to be managed over the next 5 years.</p> <p>The project will involve:</p> <ul style="list-style-type: none"><li>• Workforce redesign, where appropriate HCPs will be trained in the use of new imaging technology, and trained to give treatment to patients according to agreed pathways</li><li>• Implementation of new technology to allow improvements in the management of specific patient groups, as well as an increase in the number of patients that can be imaged and treated within the eye unit</li><li>• Initiation of virtual clinics for medical retinal patients, as well as for patients referred from the diabetic screening service and additional macular treatment clinics</li></ul> <p>These changes will be implemented and embedded by the redesign of patient pathways and ongoing training and development of staff.</p> |
| <b>Expected benefits to patients, the NHS and Bayer</b> | <p><b>Benefits for Patients:</b></p> <ul style="list-style-type: none"><li>• Improved outcomes by receiving treatment in line with NICE guidance</li><li>• Improve time to diagnosis and first treatment</li><li>• Less patients having to travel long distances to other centres for complex conditions and diagnosis</li><li>• Access to state of the art imaging technology</li><li>• Improved patient experience</li></ul> <p><b>Benefits for the NHS:</b></p> <ul style="list-style-type: none"><li>• Reducing costs associated with out of area referrals</li><li>• Enhancing the profile of the hospital and the ophthalmology unit across both Somerset and Dorset</li><li>• Improving staff satisfaction and retention by workforce redesign and an increase in opportunities for development</li></ul>  |

|                   |   |
|-------------------|---|
|                   | <b>Benefits for Bayer:</b> <ul style="list-style-type: none"><li>• An example of working in partnership with the NHS to deliver innovative service improvements for patients across an entire ophthalmology service and to build reputation</li><li>• Improving NICE-approved medicines optimisation of injectable therapies, of which Bayer's aflibercept is one, in line with national guidelines due to improving capacity for provision</li><li>• Better understanding of Yeovil Hospital and patients' needs</li></ul> |
| <b>Start date</b> | September 2017  |

Date of Preparation: August 2017

Job bag number: UKEYL04170087c